| 1 |
Breier D, Peer D. Genome editing in cancer: Challenges and potential opportunities. Bioactive Materials 2023;21:394-402. [DOI: 10.1016/j.bioactmat.2022.08.013] [Reference Citation Analysis]
|
| 2 |
Ilahibaks NF, Hulsbos MJ, Lei Z, Vader P, Sluijter JPG. Enabling Precision Medicine with CRISPR-Cas Genome Editing Technology: A Translational Perspective. Advances in Experimental Medicine and Biology 2023. [DOI: 10.1007/978-981-19-5642-3_20] [Reference Citation Analysis]
|
| 3 |
Cai W, Liu J, Chen X, Mao L, Wang M. Orthogonal Chemical Activation of Enzyme-Inducible CRISPR/Cas9 for Cell-Selective Genome Editing. J Am Chem Soc 2022;144:22272-80. [PMID: 36367552 DOI: 10.1021/jacs.2c10545] [Reference Citation Analysis]
|
| 4 |
Fachel FNS, Frâncio L, Poletto É, Schuh RS, Teixeira HF, Giugliani R, Baldo G, Matte U. Gene editing strategies to treat lysosomal disorders: The example of mucopolysaccharidoses. Adv Drug Deliv Rev 2022;191:114616. [PMID: 36356930 DOI: 10.1016/j.addr.2022.114616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Demirci S, Essawi K, Germino-Watnick P, Liu X, Hakami W, Tisdale JF. Advances in CRISPR Delivery Methods: Perspectives and Challenges. CRISPR J 2022;5:660-76. [PMID: 36260301 DOI: 10.1089/crispr.2022.0051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Touzdjian Pinheiro Kohlrausch Távora F, de Assis dos Santos Diniz F, de Moraes Rêgo-machado C, Chagas Freitas N, Barbosa Monteiro Arraes F, Chumbinho de Andrade E, Furtado LL, Osiro KO, Lima de Sousa N, Cardoso TB, Márcia Mertz Henning L, Abrão de Oliveira Molinari P, Feingold SE, Hunter WB, Fátima Grossi de Sá M, Kobayashi AK, Lima Nepomuceno A, Santiago TR, Correa Molinari HB. CRISPR/Cas- and Topical RNAi-Based Technologies for Crop Management and Improvement: Reviewing the Risk Assessment and Challenges Towards a More Sustainable Agriculture. Front Bioeng Biotechnol 2022;10:913728. [DOI: 10.3389/fbioe.2022.913728] [Reference Citation Analysis]
|
| 7 |
Rasul MF, Hussen BM, Salihi A, Ismael BS, Jalal PJ, Zanichelli A, Jamali E, Baniahmad A, Ghafouri-Fard S, Basiri A, Taheri M. Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy. Mol Cancer 2022;21:64. [PMID: 35241090 DOI: 10.1186/s12943-021-01487-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 8 |
Kanduri V, LaVigne D, Larsen J. Current Advances Toward the Encapsulation of Cas9. ACS Macro Lett 2021;10:1576-89. [PMID: 35549133 DOI: 10.1021/acsmacrolett.1c00538] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Gutkin A, Rosenblum D, Peer D. RNA delivery with a human virus-like particle. Nat Biotechnol 2021. [PMID: 34773124 DOI: 10.1038/s41587-021-01124-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 10 |
Kang YK, Lee J, Im SH, Lee JH, Jeong J, Kim DK, Yang SY, Jung K, Kim S, Chung HJ. Cas9 conjugate complex delivering donor DNA for efficient gene editing by homology-directed repair. Journal of Industrial and Engineering Chemistry 2021;102:241-50. [DOI: 10.1016/j.jiec.2021.07.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Aquino-Jarquin G. Current advances in overcoming obstacles of CRISPR/Cas9 off-target genome editing. Mol Genet Metab 2021:S1096-7192(21)00766-6. [PMID: 34391646 DOI: 10.1016/j.ymgme.2021.08.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 12 |
Hakakzadeh Z, Yekehfallah V, Ebrahimiyan H, Sayadmanesh A, Basiri M. Application of Genome-Editing Technologies for Off-the-Shelf T Cell-Based Cancer Immunotherapy. Precis Med Clin OMICS 2021;1. [DOI: 10.5812/pmco.116796] [Reference Citation Analysis]
|
| 13 |
Ma S, Lv J, Feng Z, Rong Z, Lin Y. Get ready for the CRISPR/Cas system: A beginner's guide to the engineering and design of guide RNAs. J Gene Med 2021;:e3377. [PMID: 34270141 DOI: 10.1002/jgm.3377] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 14 |
Dong W, Kantor B. Lentiviral Vectors for Delivery of Gene-Editing Systems Based on CRISPR/Cas: Current State and Perspectives. Viruses 2021;13:1288. [PMID: 34372494 DOI: 10.3390/v13071288] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 15 |
Dacoba TG, Anthiya S, Berrecoso G, Fernández‐mariño I, Fernández‐varela C, Crecente‐campo J, Teijeiro‐osorio D, Torres Andón F, Alonso MJ. Nano‐Oncologicals: A Tortoise Trail Reaching New Avenues. Adv Funct Mater 2021;31:2009860. [DOI: 10.1002/adfm.202009860] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 16 |
Perrier S, Michell-Robinson MA, Bernard G. POLR3-Related Leukodystrophy: Exploring Potential Therapeutic Approaches. Front Cell Neurosci 2020;14:631802. [PMID: 33633543 DOI: 10.3389/fncel.2020.631802] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 17 |
Dammes N, Peer D. Paving the Road for RNA Therapeutics. Trends Pharmacol Sci 2020;41:755-75. [PMID: 32893005 DOI: 10.1016/j.tips.2020.08.004] [Cited by in Crossref: 108] [Cited by in F6Publishing: 107] [Article Influence: 36.0] [Reference Citation Analysis]
|
| 18 |
Stansel T, Wickline SA, Pan H. NF-κB Inhibition Suppresses Experimental Melanoma Lung Metastasis. J Cancer Sci Clin Ther 2020;4:256-65. [PMID: 32954352 DOI: 10.26502/jcsct.5079070] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
